Drugs / EP0089
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07030478 | Sep 2025 → Mar 2028 expected | cancer | Ellipses Pharma | Not yet recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-29 | Genome & Company | 지놈앤컴퍼니, 엘립시스파마에 원료의약품 공급… EP0089 임상 본격화 genomecom.co.kr ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EP0089 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07030478 ↗ |
| Modality | Monoclonal antibody | “Monoclonal Antibody EP0089” NCT07030478 ↗ |
| Route | Intravenous | “EP0089 will be initially administered by intravenous (IV) infusion” NCT07030478 ↗ |